Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$15.56 USD
-0.48 (-2.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $15.58 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KROS 15.56 -0.48(-2.99%)
Will KROS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KROS
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
Other News for KROS
Is KROS primed for upward momentum? Crossed Above 200 Day Moving Average shows up after rising 2.69%
200 Day Moving Average Resistance appears for KROS after 1.14% move
Pocket Pivot appears for KROS after 1.61% move
MACD Bearish Signal Line Cross appears for KROS after 0.7% move
The technical outlook for KROS is unchanged after it falls 0.63% on September 12